Literature DB >> 32329851

ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.

Y-F Jin1, Y-T Huang, P-F Chen.   

Abstract

OBJECTIVE: The purpose of this study was to explore the role of ANXA3 in lung cancer cell resistance to oxaliplatin (OXA).
MATERIALS AND METHODS: After adding different concentrations of Ox, A549, and A549/Ox cell viability were examined using cell counting kit-8 (CCK-8) assay, and the mRNA and protein expressions of ANXA3 were analyzed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot, respectively. After treating cells with 5 μg/mL and 15 μg/mL Ox for 24 hours and knocking down ANXA3, qRT-PCR, CCK8, flow cytometry, transwell, and BrdU assays were performed to examine ANXA3 expression level, cell viability, apoptosis, migration, and proliferative capacities, respectively. In addition, Western blot was performed to detect the protein expression of c-caspase 3.
RESULTS: The higher the concentration of Ox added, the worse the cell viability. Meanwhile, ANXA3 expression in A549/Ox cells was found remarkably higher than that in normal A549 cells. After treated with different concentrations of Ox for 24 hours, the cell viability, migration capacity and cell proliferation of A549 cells were found remarkably decreased, while the opposite results were observed in cell apoptosis and C-caspase 3 protein expression, and the Ox treatment group was evidently lower than control group.
CONCLUSIONS: Knockdown of ANXA3 may be able to inhibit the resistance of LCa cells to OXA.

Entities:  

Year:  2020        PMID: 32329851     DOI: 10.26355/eurrev_202004_20838

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

Review 1.  Role of annexin A3 in breast cancer (Review).

Authors:  Alpaslan Ozturk
Journal:  Mol Clin Oncol       Date:  2022-05-12

Review 2.  Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data.

Authors:  Mohammed Toufiq; Jessica Roelands; Mohamed Alfaki; Basirudeen Syed Ahamed Kabeer; Marwa Saadaoui; Arun Prasath Lakshmanan; Dhinoth Kumar Bangarusamy; Selvasankar Murugesan; Davide Bedognetti; Wouter Hendrickx; Souhaila Al Khodor; Annalisa Terranegra; Darawan Rinchai; Damien Chaussabel; Mathieu Garand
Journal:  Immunology       Date:  2020-08-31       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.